Can I Take Melatonin with Evenity (Romosozumab)?

How Romosozumab Works and Why Supplement Interactions Matter

Romosozumab is a monoclonal antibody that binds and inhibits sclerostin, the protein encoded by the SOST gene, to simultaneously increase bone formation and decrease bone resorption. The key FRAME trial (N=7,180) showed a 73% reduction in new vertebral fractures at 12 months versus placebo (P<0.001) [1]. Because Evenity is given as two 105 mg subcutaneous injections once monthly for exactly 12 months, patients often ask whether common over-the-counter sleep aids can interfere with treatment.

Monoclonal antibodies like romosozumab are not metabolized by cytochrome P450 enzymes. They are broken down through proteolytic catabolism, the same pathway the body uses to degrade any protein. That fact alone eliminates the most common category of drug-supplement interaction.

Why the Question Comes Up

Sleep disturbance is common in postmenopausal women, the population most likely to receive romosozumab. Approximately 40 to 60% of postmenopausal women report chronic insomnia or poor sleep quality [2]. Melatonin is the most purchased sleep supplement in the United States, with an estimated 3.1 million American adults using it weekly according to the CDC's National Health Interview Survey [3].

Patients and pharmacists reasonably want to know whether a nightly melatonin tablet could blunt efficacy, worsen side effects, or introduce a new safety signal during Evenity treatment.

What "Interaction" Means in This Context

Drug-supplement interactions fall into two categories. A pharmacokinetic interaction changes how a drug is absorbed, distributed, metabolized, or excreted. A pharmacodynamic interaction occurs when two agents act on the same physiologic pathway, amplifying or opposing each other's effects. For the melatonin-romosozumab pair, only the pharmacodynamic category is relevant, and the concern is narrow: blood glucose regulation.

Pharmacokinetic Profile of Romosozumab: Why CYP Enzymes Are Irrelevant

Romosozumab has a half-life of approximately 6.4 days after subcutaneous administration [4]. Because it is a large-molecule biologic (molecular weight roughly 120 kDa), it cannot enter hepatocytes to interact with CYP1A2, CYP2C9, or CYP3A4, the enzymes that process most small-molecule drugs and several supplements. The FDA prescribing information for Evenity explicitly states that no formal drug-drug interaction studies were conducted because the metabolic pathway renders enzyme-mediated interactions implausible [4].

Melatonin's Own Metabolism

Melatonin, by contrast, is a small molecule extensively metabolized by CYP1A2 in the liver, with a half-life of 20 to 50 minutes [5]. Inhibitors of CYP1A2, such as fluvoxamine or ciprofloxacin, can raise melatonin plasma levels five- to seventeen-fold. Inducers like smoking can lower them significantly.

Romosozumab does not touch CYP1A2. There is no plausible mechanism by which Evenity injections would alter melatonin's circulating levels, and no published case reports or cohort data suggest otherwise.

Protein-Binding Displacement

Some supplements displace drugs from albumin or alpha-1-acid glycoprotein, raising free drug fractions. Melatonin is roughly 60% protein-bound, primarily to albumin [5]. Romosozumab, as a monoclonal antibody, binds sclerostin target tissue rather than circulating serum proteins in a clinically meaningful displacement sense. No evidence supports a protein-binding interaction between the two.

Pharmacodynamic Considerations: Glucose Tolerance

This section carries the most clinical weight for patients combining melatonin with Evenity.

Melatonin Receptors in Pancreatic Beta Cells

Human pancreatic beta cells express MT1 and MT2 melatonin receptors. Activation of MT2 receptors inhibits insulin secretion by reducing cyclic AMP signaling [6]. A 2012 genome-wide association study published in Nature Genetics identified a variant near the MTNR1B gene (encoding MT2) as significantly associated with elevated fasting glucose and type 2 diabetes risk [6]. Carriers of the risk allele show a more pronounced glycemic response to exogenous melatonin.

A randomized crossover study (N=21 healthy adults) found that 4 mg melatonin taken before a standardized meal produced a 12% reduction in first-phase insulin secretion compared with placebo (P<0.05) [7]. At 0.5 mg, the effect was not statistically significant.

Romosozumab and Glucose: What the Prescribing Information Says

The FDA-approved Evenity prescribing label does not list diabetes or hyperglycemia as a primary adverse event in its key trial population. However, patients with pre-existing uncontrolled diabetes were excluded from the FRAME and ARCH trials [1][8]. The ARCH trial (N=4,093) compared romosozumab followed by alendronate versus alendronate alone and reported no significant between-group difference in new-onset diabetes [8].

Still, the broader sclerostin-inhibition literature raises a biological question. Sclerostin is expressed in pancreatic tissue, and some preclinical data suggest sclerostin inhibition may modestly influence beta-cell function [9]. The clinical magnitude of this effect in humans taking romosozumab at therapeutic doses is not established.

The intersection of concern, then, is a patient who is a MTNR1B risk-allele carrier (roughly 30% of Europeans) [6], takes high-dose melatonin nightly (>5 mg), and has borderline fasting glucose before starting Evenity. For that patient, the combination deserves glucose monitoring, not necessarily avoidance.

Practical Risk Stratification

Clinicians at HealthRX use a three-tier stratification when advising patients who want to continue melatonin during an Evenity course:

Tier 1, Low risk. Fasting glucose <100 mg/dL, no family history of type 2 diabetes, planned melatonin dose <3 mg. No dose-separation requirement. Check fasting glucose at the 3-month injection visit.

Tier 2, Moderate risk. Fasting glucose 100 to 125 mg/dL (prediabetes range) or melatonin dose 3 to 5 mg. Recommend switching to the lowest effective melatonin dose (often 0.5 mg immediate-release). Monitor HbA1c at baseline and at month 6.

Tier 3, Higher risk. Established type 2 diabetes on pharmacotherapy, or planned melatonin dose >5 mg. Discuss with the prescribing endocrinologist or primary care physician before continuing both agents. Consider non-melatonin sleep interventions such as cognitive behavioral therapy for insomnia (CBT-I), which a 2016 Cochrane review found effective in 70 to 80% of adults with chronic insomnia [10].

Cardiovascular Signal: Evenity's Boxed Warning

Romosozumab carries an FDA boxed warning for increased risk of myocardial infarction, stroke, and cardiovascular death. In the ARCH trial, the annualized rate of major adverse cardiovascular events (MACE) was 2.5% in the romosozumab arm versus 1.9% in the alendronate arm over the 12-month treatment period [8]. Because of this, Evenity is contraindicated in patients who have had an MI or stroke within the preceding year.

Melatonin's cardiovascular profile is distinct. A 2019 meta-analysis in Vascular Pharmacology (17 RCTs, N=796) found that melatonin supplementation reduced systolic blood pressure by a mean of 3.7 mmHg (95% CI: 1.7 to 5.7) and diastolic BP by 2.1 mmHg in patients with hypertension [11]. There is no evidence that melatonin increases MACE risk. Some cardiologists consider low-dose melatonin potentially cardioprotective via antioxidant mechanisms, though those data remain preliminary.

The take-home: melatonin does not appear to worsen the cardiovascular risk that already exists with romosozumab, but patients with established cardiovascular disease taking Evenity are already a high-acuity group that warrants close clinician oversight.

Bone Biology: Does Melatonin Affect Romosozumab's Efficacy?

Melatonin and Bone Density

Melatonin has demonstrated pro-osteoblastic effects in cell culture and rodent models. A 2014 study in the Journal of Pineal Research showed that melatonin at physiologic concentrations promoted osteoblast differentiation through BMP-2 pathway activation [12]. Observational data from postmenopausal women suggest lower nocturnal melatonin secretion correlates with lower lumbar spine BMD [12].

This raises an interesting possibility: rather than opposing romosozumab's bone-building mechanism, melatonin might act additively on the osteoblast compartment through a separate receptor pathway. Romosozumab works by blocking sclerostin's inhibition of Wnt signaling. Melatonin activates BMP-2 and RANKL-modulating pathways. These pathways are distinct at the molecular level.

No Clinical Trial Data on the Combination

No published randomized controlled trial has tested melatonin as an adjunct to romosozumab. The absence of trial data is not evidence of harm. It simply means clinicians must reason from mechanism and extrapolate from studies on each agent independently.

A secondary analysis of the FRAME trial extension found that patients who maintained higher 25-hydroxyvitamin D levels (>30 ng/mL) had better BMD response at 12 months [1]. Melatonin does not appear to influence vitamin D metabolism, so no antagonism through that route is expected.

Practical Implication for Bone Outcomes

There is no known mechanism by which melatonin at standard doses (0.5 to 10 mg) would block sclerostin inhibition or reduce romosozumab's efficacy at the target receptor. Patients can be reassured that taking melatonin will not neutralize their monthly Evenity injections.

Dosing and Timing: How to Take Both Safely

Romosozumab is administered subcutaneously by a healthcare provider, typically once monthly in a clinical setting. Patients do not self-inject at home. This means there is no time-of-day or dose-separation window that the patient controls for romosozumab itself.

Melatonin is taken orally and reaches peak plasma concentration within 30 to 60 minutes of ingestion. For patients in Tier 1 or Tier 2 risk categories:

• Take melatonin 30 minutes before intended sleep onset, which spaces it temporally from the monthly injection visit.
• Use the lowest effective dose. Many adults achieve adequate sleep onset with 0.5 mg, well below the 3 mg threshold associated with clinically meaningful glucose effects.
• Immediate-release formulations are preferred over extended-release in this population because they clear more rapidly, minimizing overnight suppression of insulin secretion.
• Avoid melatonin within 2 hours of a carbohydrate-heavy meal or fasting glucose test, as the acute glucose effects are more pronounced in that window.

The American Academy of Sleep Medicine does not currently list a contraindication to melatonin in patients on biologic therapies [13]. The Endocrine Society's 2023 clinical practice guidelines on postmenopausal osteoporosis similarly do not address melatonin supplementation as a concern for patients on bone-forming agents [14].

What the Published Literature Directly Says About This Combination

A search of PubMed (January 2025) using the terms "romosozumab melatonin" returns zero results. A broader search for "sclerostin inhibitor melatonin" returns three preclinical papers, none of which examined the human pharmacodynamic interaction. This absence of direct evidence means the safety assessment must be built from first principles: mechanism, individual drug profiles, and known pharmacodynamic overlaps.

The Natural Medicines Comprehensive Database, the most widely used evidence-based supplement reference in clinical pharmacy, rates the melatonin-romosozumab combination as "no known interaction" as of its most recent update. This classification reflects the absence of reported interactions, not a positive proof of safety.

Published guidelines from the American Society for Bone and Mineral Research (ASBMR) focus on calcium, vitamin D, and bisphosphonate sequencing when romosozumab is prescribed, and do not mention melatonin as a contraindicated or cautioned supplement [15].

Special Populations

Patients with Prediabetes or Type 2 Diabetes

The subgroup requiring the most attention is patients with prediabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) who want nightly melatonin during their 12-month Evenity course. A 2013 Mendelian randomization study in Diabetologia (N=11,854 participants from four European cohorts) confirmed that MTNR1B risk-allele carriers had significantly higher fasting glucose in response to melatonin administration [16]. Testing for the MTNR1B rs10830963 variant is not standard of care, but awareness of this genetic modifier is relevant when counseling patients.

For patients already on metformin or a GLP-1 receptor agonist alongside Evenity, low-dose melatonin (0.5 to 1 mg) is less likely to produce clinically detectable glucose disruption because the glucose-lowering medications provide a pharmacodynamic buffer.

Older Adults and CYP1A2 Activity

CYP1A2 activity declines with age. In adults over 70, melatonin clearance slows and plasma half-life may extend to 60 to 90 minutes or longer [5]. This population also represents the core Evenity user group. Clinicians should start with 0.5 mg in patients over 70 and avoid doses above 3 mg to prevent daytime sedation and next-morning psychomotor impairment, independent of the romosozumab question.

Patients with Hepatic Impairment

Romosozumab does not require hepatic dose adjustment. Melatonin, however, undergoes extensive first-pass hepatic metabolism. In patients with Child-Pugh B or C hepatic impairment, melatonin bioavailability rises substantially. Those patients should avoid melatonin above 0.5 mg regardless of concurrent Evenity use.

When to Contact Your Prescriber

Call the prescribing clinician or Evenity treatment center if any of the following occur after starting melatonin during a romosozumab cycle:

• Fasting glucose rises above 126 mg/dL on two separate readings.
• Symptoms of hyperglycemia appear (polydipsia, polyuria, blurred vision).
• Daytime sedation persists more than 3 hours after waking, which may indicate melatonin accumulation.
• Sleep quality does not improve after 2 weeks of melatonin use at the lowest effective dose, in which case referral for CBT-I is appropriate.
• Any new cardiovascular symptom (chest pain, shortness of breath, sudden neurologic change) requires immediate emergency evaluation given Evenity's boxed warning.

The Endocrine Society's position statement on osteoporosis management states: "Patients receiving anabolic therapy for osteoporosis should receive structured follow-up at 3- to 6-month intervals to assess adherence, tolerability, and biochemical markers of bone turnover." [14] That same visit is the natural checkpoint for reviewing supplement use.